Anti-PPP1R1B monoclonal antibody

Protein phosphatase 1 regulatory subunit 1B (PPP1R1B), also known as dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP-32), is a highly abundant and well-studied neuronal protein. This protein is primarily expressed in medium-spiny neurons of the striatum, a brain region that is critical for motor control, reward processing, and various cognitive functions.

DARPP-32 plays a central role in integrating dopaminergic and glutamatergic neurotransmission in the striatum. When phosphorylated, DARPP-32 acts as a potent inhibitor of protein phosphatase-1 (PP1), a ubiquitous serine/threonine phosphatase. This inhibition of PP1 allows for the propagation of various signaling cascades downstream of dopamine and glutamate receptors, affecting neuronal excitability, synaptic plasticity, and gene expression. The phosphorylation state of DARPP-32 is tightly regulated by a balance of kinase and phosphatase activities. Dopamine D1 receptor stimulation leads to DARPP-32 phosphorylation, while glutamatergic NMDA receptor activation promotes its dephosphorylation. This makes DARPP-32 a critical node in the integration of these two major neurotransmitter systems within striatal neurons.

Figure 1. Central role of the DARPP-32/PP-1 pathway in signal transduction in medium spiny neurons.
(Source: Greengard, P. et al., 1999)

DARPP-32 has emerged as a key player in the pathogenesis of diverse neurological and psychiatric disorders. Dysregulation of DARPP-32 has been implicated in the etiology of conditions including Parkinson's disease, schizophrenia, and addiction, underscoring its significance in central nervous system dysfunction. Furthermore, the aberrant expression and activity of the PPP1R1B gene, encoding DARPP-32, have been observed in specific cancer types. In these malignancies, the overexpression of DARPP-32 and its isoforms may exert detrimental effects by promoting disease progression and conferring resistance to therapeutic interventions. The multifaceted involvement of DARPP-32 in both neurological and neoplastic contexts highlights its potential as a promising target for therapeutic interventions and underscores the need for further investigations to unravel the underlying molecular mechanisms and clinical implications associated with its dysregulation in these complex disorders.

Anti-protein phosphatase 1, regulatory (inhibitor) subunit 1B monoclonal antibody
Anti-DARPP32 monoclonal antibody
Anti-DARPP-32 monoclonal antibody
Anti-protein phosphatase 1 regulatory subunit 1B monoclonal antibody
Anti-dopamine and cAMP-regulated neuronal phosphoprotein 32 monoclonal antibody